Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID
8.12.2021 03:01:00 EET | Business Wire | Press release
Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, welcomes the recommendation that DIFICLIRTM (fidaxomicin) should be used for the initial treatment and first recurrence of Clostridioides difficile infection (CDI) in updated guidance from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).1 ESCMID guidance is now consistent with the Infectious Disease Society of America (IDSA) guidelines which also recommend fidaxomicin for initial and recurrent episodes of CDI.1,2
In one clinical trial the rates of clinical cure with fidaxomicin were noninferior to those with vancomycin (88.2% with fidaxomicin and 85.8% with vancomycin).3 Significantly fewer patients in the fidaxomicin group than in the vancomycin group had a recurrence of the infection (15.4% vs. 25.3%, P=0.005).3 Clinical cure noninferiority was also demonstrated in a separate trial (87.7% with fidaxomicin and 86.8% with vancomycin).4 In this trial similar outcomes were seen in the modified intention-to-treat treatment groups, although patients receiving concomitant antibiotics for other infections had a higher cure rate with fidaxomicin than vancomycin (90.2% with fidaxomicin and 73.3% with vancomycin, P=0.031).4
Healthcare-associated CDI infections represent a burden to acute care hospitals in Europe with around 125,000 cases estimated annually.5 CDI frequently causes healthcare-associated infectious diarrhoea and is associated with considerable morbidity, mortality and financial burden.6 Recurrence of disease is a significant problem, with 20–30% of patients experiencing a recurrent episode following initial resolution of CDI.7
“This recognition of the important role that DIFICLIRTM can play in helping to reduce the rate of recurrence is good news for patients and clinicians across Europe,” says Adrian Hill, Head of International Operations, Tillotts Pharma. “Fidaxomicin is not only effective for the treatment of CDI, it also reduces recurrence, something which impacts the lives of patients and costs health systems millions of euros every year.”
“This new guideline from ESCMID is welcome, and notably brings Europe into line with recent U.S. (IDSA) guidance,” comments Professor Mark Wilcox, MD, Consultant, and group member and co-author of the ESCMID CDI treatment guideline and Professor in Medical Microbiology, at Leeds Teaching Hospitals & University of Leeds, UK. “This provides clinicians with clarity, allowing best practice to be adopted at pace. Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.”
Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation resistance and restricting opportunities for C. difficile recurrence.3
ENDS
Tillotts Pharma AG – Baslerstrasse 15 – 4310 Rheinfelden – Phone +41 61 935 2626 – www.tillotts.com
Job code: PM-DIF-ALL-00030
Date of preperation: November 2021
References
- Van Prehn J et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection, 2021. https://doi.org/10.1016/j.cmi.2021.09.038.
- Johnson S et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021;73(5):e1029-44.
- Louie TJ et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422–31.
- Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8. PMID: 22321770.
- European Centre for Disease Prevention and Control (ECDC). Clostridium difficile infections – Facts and surveillance. https://www.ecdc.europa.eu/en/clostridium-difficile-infections/facts. Accessed October 2021
- Tresman R and Goldenberg SD. Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes. J Antimicrob Chemother 2018;73:2851-2855.
- Deshpande A, Pasupuleti V, Thota P et al (2015) Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 36:452–460 10.
About DIFICLIRTM
DIFICLIRTM is a macrocyclic anti-bacterial agent. It is formulated as film-coated tablets for oral administration. The tablets are indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg. Consideration should be given to official guidelines on the appropriate use of antibacterial agents. DIFICLIRTM acts by inhibiting the bacterial enzyme RNA polymerase, resulting in rapid killing of C. difficile. It eradicates C. difficile selectively with minimal disruption to the normal intestinal flora.
About Tillotts
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.
All trademarks used or mentioned here are protected by law. © Copyright Tillotts Pharma AG. All rights reserved.
For more information, please visit www.tillotts.com
About Zeria
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit www.zeria.co.jp
Download high-resolution photos here https://www.tillotts.com/about-us/visuals/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005586/en/
Contact information
Tillotts Pharma AG
Susi Teichmann
Senior Manager Corporate Communications
Phone: +41 61 9352 759
Email: Susi.Teichmann@tillotts.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Adds Depth to Tax and Global Mobility Capabilities in Germany30.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its presence through a Collaboration Agreement with Lohr and Company (L+C), a senior-led tax advisory platform, providing practical, responsive solutions in tax compliance, cross-border tax, global mobility, and transfer pricing. Headquartered in Germany with a presence in Austria, L+C advises large multinationals and family-owned companies, family offices, foundations, and high-net-worth individuals. The firm, founded in 2001, specializes in areas such as global mobility, M&A, international tax law, country-by-country reporting, and transfer pricing, including Pillar 2 reporting. Additionally, L+C supports clients with trusts and foundations, tax compliance, payroll and financial accounting, and private financial advisory services. “Collaborating with Andersen Global represents an important step in expanding our international capabilities and strengthening the value we provide to clients navigating increasingly complex cross-border matters,” said Jörg-Andre
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 16:00:00 EEST | Press release
As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations address this challenge, Lenovo is expanding its global Security Services portfolio with a revamped cyber resiliency framework and end-to-end security offerings designed to provide a single point of accountability, help organizations reduce security complexity, cut system downtime by up to 50%, and lower
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 16:00:00 EEST | Press release
SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hypersensitivity through receptor blockade – SC0032’s approach directly addresses the upstream inflammatory drivers of chronic cough. By acting to
Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win30.6.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes. Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them. ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear. That's because the most important layer of insight–the connection between customer needs, configuration decisions and deal outcomes–only exists within CPQ. “As product complexity increases
Riskified Study: As AI Drives a Summer Travel Boom, Clunky Security and Scam Fears Threaten Merchant Conversions30.6.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released findings from global survey conducted ahead of the 2026 Summer Travel season, exploring consumer travel behavior, booking experiences, and trust in digital and AI-enabled travel tools. The survey, conducted among more than 4,000 consumers across the United States, United Kingdom, China, Japan, Mexico, Brazil, and Colombia, shows strong demand for travel heading into the summer season, alongside continued adoption of digital and AI tools in trip planning. Key findings from the Riskified 2026 Summer Travel Survey include: 81% of consumers use digital platforms for travel planning, with 26% already relying on AI like ChatGPT or Gemini. Leisure remains the dominant purpose of travel at 63%, followed by visiting friends and family (25%), going to live events (7%), and business travel (5%). 47% cite payment security and 39% cite fake or invalid tickets as top concerns when buying tickets online.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom